Why Biologics Have NO Generics: Biologics, Biosimilars & Generics | BLA, 351(k), Approval Pathways

Biologics and biosimilars are transforming modern medicine—but their regulatory pathways are far more complex than traditional drugs. In this video, we break down the complete concept of biologics, biosimilars, and generics, along with their approval pathways in the US FDA and European Medicines Agency (EMA). You will learn: ✔ Difference between small molecules and biologics ✔ What are biosimilars and how they are developed ✔ Stepwise approach: analytical, non-clinical, clinical comparison ✔ BLA pathway (351a vs 351k) explained ✔ Interchangeability in the US ✔ EU biosimilar approval process (centralized procedure) ✔ Key differences between US and EU regulations ✔ Real-world importance of biosimilars in healthcare This video is part of a complete Regulatory Affairs course designed for beginners to advanced learners. 📌 Whether you’re preparing for interviews, working in pharma, or entering regulatory affairs, this topic is essential. #Biologics #Biosimilars #RegulatoryAffairs #Pharma #DrugDevelopment #USFDA #EMA #Biotech #ClinicalResearch #PharmaceuticalIndustry #Healthcare #Biotechnology #Generics #LifeSciences #pharmaeducation #regulatoryaffairs #drugdevelopment #clinicalresearch